Lacosamide for the Treatment of Seizures in Neonates and Infants: A Retrospective Assessment of Efficacy and Tolerability.

BACKGROUND

A retrospective study was conducted to assess the safety and efficacy of lacosamide in children aged less than 24 months.

METHODS

Patients were included if they were ≤24 months when they first received lacosamide; patients were excluded if they were enrolled in research studies investigating lacosamide or if there were insufficient data in the chart. Treatment response was assessed by reviewing charts and electroencephalographic reports to determine reduction in seizure burden.

RESULTS

In this sample, 53 of 86 patients (61.63%) in status epilepticus had good response to lacosamide, defined by ≥50% reduction in seizure burden. In addition, patients' charts were reviewed until age 24 months to assess for any adverse effects attributed to maintenance lacosamide therapy, with adverse effects noted in three patients (abnormal movements in two patients, worsened seizures in one patient).

CONCLUSIONS

This study is among the largest retrospective chart reviews investigating the use of lacosamide in children and the first investigating the efficacy of lacosamide in children aged ≤24 months. Lacosamide was efficacious in reducing seizure burden in status epilepticus, and it was very well-tolerated in this age group. This study should prompt further investigation into the use of lacosamide in this age group.